A retrospective analysis was made of 122 children who had received an allogeneic haematopoietic stem cell transplantation (HSCT) for autosomal recessive osteopetrosis between 1980 and 2001. The actuarial probabilities of 5 years disease free survival were 73% for recipients of a genotype HLA-identical HSCT (n ¼ 40), 43% for recipients of a phenotype HLA-identical or one HLAantigen mismatch graft from a related donor (n ¼ 21), 40% for recipients of a graft from a matched unrelated donor (n ¼ 20) and 24% for patients who received a graft from an HLA-haplotype-mismatch related donor (n ¼ 41). In the latter group, a trend towards improvement was achieved at the end of the study period (17% before 1994, 45% after 1994, P ¼ 0.11). Causes of death after HSCT were graft failure and early transplant-related complications. Severe visual impairment was present in 42% of the children before HSCT. Conservation of vision was better in children transplanted before the age of 3 months. Final height was related to height at the time of HSCT and better preserved in children transplanted early. Most children attended regular school or education for the visually handicapped. At present, HSCT is the only curative treatment for autosomal recessive osteopetrosis and should be offered as early as possible.
A retrospective analysis was made of 122 children who had received an allogeneic haematopoietic stem cell transplantation (HSCT) for autosomal recessive osteopetrosis between 1980 and 2001. The actuarial probabilities of 5 years disease free survival were 73% for recipients of a genotype HLA-identical HSCT (n ¼ 40), 43% for recipients of a phenotype HLA-identical or one HLAantigen mismatch graft from a related donor (n ¼ 21), 40% for recipients of a graft from a matched unrelated donor (n ¼ 20) and 24% for patients who received a graft from an HLA-haplotype-mismatch related donor (n ¼ 41). In the latter group, a trend towards improvement was achieved at the end of the study period (17% before 1994, 45% after 1994, P ¼ 0.11). Causes of death after HSCT were graft failure and early transplant-related complications. Severe visual impairment was present in 42% of the children before HSCT. Conservation of vision was better in children transplanted before the age of 3 months. Final height was related to height at the time of HSCT and better preserved in children transplanted early. Most children attended regular school or education for the visually handicapped. At present, HSCT is the only curative treatment for autosomal recessive osteopetrosis and should be offered as early as possible. Bone Marrow Transplantation (2003) 32, 657-663. doi:10.1038/sj.bmt.1704194 Keywords: haematopoietic stem cell transplantation; osteopetrosis; inborn error; cord blood; optic atrophy Juvenile autosomal recessive osteopetrosis (AR-OP) is a rare disease caused by defective osteoclastic bone resorption, leading to increased skeletal mass and bone density. Secondary effects of this process of abnormal bone remodelling are deficient haematopoiesis, visual impairment, because of dysfunction of the optic nerve, and growth retardation. A minor proportion of patients show neurological deterioration, which is not clearly understood. If untreated, AR-OP is fatal, usually before the age of 5 years. 1 Recently, mutations have been identified in the ATP6i (TCIRG1) gene, encoding the a3 subunit of the vacuolar proton pump, which mediates the acidification of the bone/osteoclast interface. 2 This defect is estimated to cause half of the cases of AR-OP. 3 A different small subgroup with a milder phenotype is known to have carbonic anhydrase II deficiency. 4 Also a defect in the CIC-7 chloride channel has been demonstrated to cause osteopetrosis in a minority of cases. 5 Since 1977, allogeneic haematopoietic stem cell transplantation (HSCT) had been successfully applied in single cases and small groups of AR-OP patients. [6] [7] [8] [9] In 1994, our group reported the results in 69 patients, showing a favourable outcome of HSCT with a (genotype) HLA-identical donor. 10 Treatments with approaches other than HSCT such as corticosteroids, high doses of calcitriol (vitamin D 3 ) and interferon-g, have been disappointing. [11] [12] [13] [14] We report the results of HSCT in 122 patients treated in Europe, Costa Rica and Saudi Arabia, including the follow-up of HSCT survivors from 1994.
Patients and methods

Patients
Between 1980 and 2001, 122 patients (63 males, 59 females) received a total of 141 HSCTs for AR-OP in 20 co-operating centres in Europe, Costa Rica and Saudi Arabia (participating centres listed in an addendum to the text). In a previous report 10 , data on 69 patients were presented. Of these, 65 are included in this report; four patients transplanted before 1980 were excluded because of absence of myeloablative conditioning before HSCT and subsequent graft failure. Data on HSCTs for AR-OP during this period were collected from members of the Working Party on Inborn Errors of the European Group for Blood and Marrow Transplantation (EBMT). A retrospective analysis was made of data available up to January 2001.
Findings at diagnosis
Median age at HSCT was 6 months (range 1-105 months). Pre-HSCT, 46% of the patients had moderate haematopoietic deficiency (defined as 1-10 erythrocyte or thrombocyte transfusions pre-HSCT) and in 13% it was severe (defined as 410 erythrocyte or thrombocyte transfusions pre-HSCT). In the remaining 41% patients, the haemoglobin level and platelet counts were normal, mildly reduced (majority) or unknown. A total of 23% of the patients had moderate visual impairment defined as partial optical atrophy, reduced visual evoked potential (VEP) responses and presence of eye fixation, 42% had severe visual impairment defined as total optical atrophy, absence of VEP and roving eye movements.
Donor HLA compatibility
In all patients, HLA A, B and DR serotyping determined HLA compatibility between donor and recipient. The patients were categorized into four groups based on HLA disparity with the donor: a (genotype) HLA-identical sibling donor (group A, ''HLA ¼ ''; n ¼ 40), a (phenotype) HLA-matched unrelated donor (group B, MUD; n ¼ 20, of which two with umbilical cord blood), a (phenotype) HLA 0-1 (antigen) mismatch related donor (group C, ''HLA 0-1 a''; n ¼ 21) or an (HLA-)haplo(type)-mismatch related donor (group D, ''Haplo a''; n ¼ 41).
Conditioning
All patients received myeloablative conditioning with regimens according to protocols of the Working Party on Inborn Errors of the EBMT. The majority of the patients received busulphan, 4 or 5 mg/kg/day for 4 days orally and cyclophosphamide 50 mg/kg per day for 4 days i.v. Details of the conditioning regimes are given in Table 1 .
To improve engraftment at the first HSCT attempt, all patients without a (genotype) HLA-identical donor (groups B, C and D) received additional pretreatment with cytotoxic drugs and/or immunosuppressive antibodies. The following cytotoxic drugs were used: thiotepa 5-10 mg/kg/ day i. 15 the combination of anti-CD 11a with anti-CD 2 0.2 mg/kg/day from À3 until day +7, 16 rabbit ATG 2 mg/kg/day from day À6 or À5 until day -2 or Campath-1-G 0.2 mg/kg/day from day À8 until day -3. 17 
Graft size
The majority of patients (n ¼ 68) received unseparated marrow grafts, containing a median number of 5.8 Â 10 8 nucleated cells (range 0.34-16.0) per kg body weight. Table 1 Details of conditioning and T-cell depletion of the graft for 122 children at first HSCT for AR-OP 
T-cel depletion of the graft T-cell-depleted (TCD) grafts, excluding the grafts of mobilized peripheral blood stem cells, contained a median number of 4.3 Â 10 8 nucleated cells (range 0.20-46.0) per kg body weight (numbers are given before the T-cell depletion procedure; data on counts after the procedure were lacking). Two patients were grafted with cord blood (one case reported in detail 18 ). These grafts contained 1.23 and 1.66 Â 10 8 nucleated cells per kg body weight, respectively. Eight patients were grafted with mobilized peripheral blood stem cells (seven patients reported in detail 19 ). These grafts contained a median number of 25 Â 10 6 nucleated cells (range 12-405) per kg body weight (numbers after the procedure are given).
GVHD prophylaxis
Of the patients with unseparated marrow grafts, 4% received methotrexate only, 42% received cyclosporine A only and 54% received a combination of methotrexate and cyclosporine A as GVHD prophylaxis. A total of 54 patients received a TCD graft as GVHD prophylaxis (Table 1) . TCD was carried out by E-rosetting (n ¼ 8), Campath-1-IgM monoclonal antibody plus complement (n ¼ 28) or other methods (n ¼ 10). Of the patients with a TCD graft, 60% received no additional GVHD prophylaxis, 30% received additional cyclosporine A and 10% received a combination of methotrexate and cyclosporine A additionally. In eight patients, a positive selection of CD34 cells was performed using the CliniMACS system TM (Miltenyi Biotec, n ¼ 3) or the Ceprate SC device TM (Cellpro, n ¼ 5). 19 
Prevention of infections
To prevent infections, patients were treated in protective isolation using aseptic techniques and high-efficiency particulate air (HEPA)-filtered isolation facility. Patients received oral nonabsorbable antimicrobial drugs to suppress the gastrointestinal microflora or systemic antimicrobial prophylaxis.
Chimerism studies
Chimerism was studied by routine karyotyping, HLA typing and restriction fragment length polymorphism (RFLP) with minisatellite probes in most cases on wholeblood samples.
Definitions
Disease free survival (DFS) was defined as survival with osteoclast function, reflected by hypercalcaemia, hypercalcuria, clearing of bones shown by radiography or demonstration of osteoclast function in a bone biopsy specimen. Improvement of peripheral blood values and normalization of the spleen and liver size were also regarded as markers of recovering osteoclast function. Hypercalcaemia was considered severe if the serum calcium level exceeded 2.8 mmol/l (11.5 mg/dl).
Statistical analysis
DFS was calculated according to the method of Kaplan and Meier 20 and comparison of survival between subgroups was made using the log-rank test. The w 2 test was used for the comparison of discrete data. Comparison of growth data with reference values was made using the one-sample t-test. Paired growth data were compared using the paired t-test. P ¼ 0.05 (two-sided) was considered the limit of significance.
Results
Engraftment
Donor-derived haematopoiesis after the first HSCT was documented in 95% (37/39) recipients of a (genotype) HLA-identical graft (group A; one child was not evaluable because of early death). In the single child who received a TCD graft, failure of engraftment occurred. In this case, prompt engraftment occurred after retransplantation with unmodified HSCs. The other child was retransplanted after failure of an unmodified HSC graft and showed engraftment at the subsequent HSCT. Engraftment occurred in 15 out of 19 (79%) evaluable recipients of an HSC graft from an MUD (group B), in 11 out of 21 recipients (52%) of a (phenotype) HLA 0-1 (antigen) mismatch related donor (group C) and in 22 of 36 evaluable recipients (61%) of an (HLA-)haplo(type)-mismatch HSC graft (group D).
A total of 19 patients were retransplanted after failure of the first graft. In six patients (two HLA ¼ , one MUD and three Haplo a), this procedure resulted in sustained engraftment.
Subgroups of patients without a (genotype) HLAidentical donor (groups B, C and D) who had received different myeloablative conditioning regimes, additional myeloablation with thiotepa, etoposide or fludarabine or addition of immunosuppressive antibodies were analysed for the occurrence of engraftment. Univariate analysis showed that the occurrence of engraftment was not significantly affected by age at HSCT, the busulphan dosage or the addition of thiotepa, etoposide or fludarabine to the myeloablative conditioning regime. Also the addition of immunosuppressive antibodies or the method of TCD was found to have no effect on engraftment. However, the numbers of patients per subgroup were small.
Survival
Of 122 patients, 56 (46%) were alive with osteoclast function at last evaluation (Table 2) . Median period of follow-up after the first HSCT was 5 years (range 0.5-16.5 years). The Kaplan-Meier curves depicting DFS are shown in Figure 1 . DFS according to the type of donor was significantly better in patients receiving a (genotype) HLAidentical graft (73%) as compared to each of the other patient groups (MUD 40%, HLA 0-1 a 43% and haploa24%; all Po0.03). The differences in DFS between the latter three groups were not significant. If only the first HSCT is taken into account, there was a trend towards a better DFS with an HLA 0-1a donor or an MUD, compared with patients with a haplo a donor (P ¼ 0.06). Patients with a haploaHSCT before 1994 (n ¼ 30) had a DFS of 17%, compared to 45% of the patients transplanted after 1994 (n ¼ 11). Although the trend shows improvement, the numbers were too small to make the difference statistically significant (P ¼ 0.11). Analysis of HLA ¼ , MUD and HLA 0-1a HSCT before and after 1994 did not show significant differences in DFS.
In addition to 56 children with normal osteoclast function after successful HSCT, six other patients survived with persistent osteopetrosis. They showed autologous recovery after one (n ¼ 4) or two (n ¼ 2) HSCTs.
Of 122 children, 61 (50%) died following HSCT. In only one child the cause of death was not related to osteopetrosis or HSCT (car accident; in the analysis, the survival of this child was censored). In two children, the cause of death was unknown. In all other cases, the main cause of death was related to graft failure or the early toxic effects of myeloablative conditioning (Table 3) . In four children, death was caused by neurological causes (brain abscess one, encephalitis one, hydrocephalus one and cerebral degeneration one). In one, an associated neurodegenerative disease, not suspected before HSCT, was responsible for death. Six children died of other causes (anaphylactic shock one, multi organ failure four and renal failure one). There was no independent effect of the patient's age at HSCT on survival.
GVHD
Of the 116 evaluable patients, 17 (15%) developed acute GVHD, of whom four grades III-IV. Of the 112 evaluable patients, six (5.3%) developed chronic GVHD, of whom one extended.
Follow-up related to osteopetrosis
Severe hypercalcaemia, an early complication of HSCT for AR-OP, developed in eight out of 50 evaluable patients (16%). The difference in risk of severe hypercalcaemia in children transplanted before the age of 2 years (2/40; 5%) and after this age (6/10; 60%) was highly significant (Po0.01).
At the time of HSCT, 34 of 98 evaluable patients (35%) had normal vision, 23 had moderate visual impairment (23%) and 41 patients had severe visual impairment (42%). A total of 14 of 29 children (48%), transplanted before the age of 3 months, had no visual impairment. In children 4-6 months of age, normal vision at the time of HSCT was present in 14/27 (52%), whereas in children older than 6 months, normal vision was present in only 6/42 (14%). After successful HSCT, there was no further deterioration of vision in 29 of 42 evaluable patients (69%). Only three patients (7%) showed an improvement of vision after HSCT, in contrast, 10 (24%) showed a further deterioration. There was a trend towards better conservation of vision in the age group of the less than or equal to 3 months of age at HSCT (P ¼ 0.06).
Growth measurements before HSCT or at last followup after HSCT were available for 44 patients with sustained engraftment and osteoclast function (Figure 2) .
Unfortunately, longitudinal growth data of individual children were not available. However, for 18 children, measurements were paired (height before HSCT and at last follow-up). Before HSCT, patients with AR-OP had a mean SD-score (SDS) for their height, based on age and sex-specific reference values 21 , of À3.0, which was significantly (Po0.001) lower than zero (average growth). Delay of HSCT resulted in a significantly lower SDS at HSCT (P ¼ 0.03). The mean SDS at last follow-up (median followup period 5 years after HSCT) was -2.7, which was not significantly higher than before HSCT. This implicates that, on average, children grow parallel to the percentile present at the time of HSCT. Of the 18 patients with paired data, 11 (61%) had a height at the same SDS or better and seven (39%) had a height at a lower SDS at the last followup after HSCT. Also for these children, mean SDS pre-HSCT and at last follow-up did not differ significantly (P ¼ 0.82).
Most of the children attended regular school. Of the children with a visual disability, 22 needed special education.
Discussion
AR-OP is a rare congenital disease usually with a fatal outcome at a young age. 1 Furthermore, early and irreversible severe impairment of vision develops. 22 In selected cases, surgical decompression of the optical nerve might be indicated to prevent further deterioration awaiting HSCT. 23 In some patients, calcitriol in high dosages 11 or interferon gamma 12 might slow the progression of the disease. Improvement of haematopoiesis can be achieved with prednisone. 13, 14 However, HSCT is today the only curative treatment.
We present the result of 122 patients, following an earlier report on 65 of them. 10 The data underscore our earlier observation that a genetically HLA-identical donor is preferable (DFS about 70%). Over the years, the results of HSCT with a (phenotype) HLA-0-1 (antigen) mismatch related donor or an MUD (about 40% DFS) have been stable, whereas there is a trend towards a better survival in HSCT with an (HLA-)haplo(type)-mismatch related donor since 1994 (P ¼ 0.11).
Owing to the long follow-up period and a larger cohort of patients, we were able to present more reliable data about long-term outcome after HSCT. The data show clearly that early HSCT is indicated to preserve vision and final height as much as possible. There is also a much lower risk of severe hypercalcaemia in infants compared to older children. We demonstrated that after successful HSCT, the majority of children had no further deterioration of vision and that conservation of vision is best in children transplanted before the age of three months.
In addition, we showed that there is a progressive deterioration of growth before HSCT, resulting in a height SD-score (SDS) far below average (À3.0 SD). Growth shortly before HSCT and at last follow up (À2.7 SD) was not significantly different, suggesting that most of the patients will continue to grow along an SDS line on the Age (years) Figure 2 Growth of children at the time of HSCT and at last follow-up
Closed circles: height SDS at the time of HSCT. Open circles: height SDS at last follow-up after HSCT. Height SDS are based on age and sex-specific reference values. 21 SDS 0 reflects average growth, SDS À2 the lower limit of normal growth in a healthy population. growth curve after successful HSCT. However, in a number of patients with paired growth measurements (7/18, 39%), this SDS was at a lower level than before HSCT, suggesting that there might be a subgroup with progressive growth impairment, related to the original disease or to HSCT variables (eg more intense cytotoxic pretreatment). The numbers were too small to further analyse this observation.
If a (genotype) HLA-identical donor is not available, a prompt search to find a (phenotype) HLA-0-1 (antigen) mismatch related donor or an MUD is indicated, because the results (about 40% DFS) tend to be better than with an (HLA-)haplo(type)-mismatch related donor (about 25% DFS). However, important improvement after haploa HSCT has been achieved recently using two consecutive high-quantity peripheral HSCT after highly immunosuppressive pretreatment. 19 We observed that haploaHSCTs performed after 1994 tend to have a better DFS (about 45%) than before 1994 (17%), resulting in a similar DFS compared to an MUD or HLA 0-1adonor (about 40%). If no MUD or HLA 0-1adonor is available within a very limited period of time (eg within 1 month), it is advisable to proceed to a haploaHSCT. The dismal long-term prognosis of AR-OP 1 has to be weighed against the risk of haploaHSCT. 19 The frequency of early toxicity, that is pulmonary hypertension and veno-occlusive disease and risk of long-term sequelae (eg maybe severe short stature) in this group of patients makes it difficult to define the most appropriate conditioning regime.
We strongly suspect that a number of cases with pulmonary hypertension are hidden in the series of cases and are reported as idiopathic pneumonitis. Since pulmonary hypertension masquerades as pneumonitis, specific diagnostic procedures (eg cardiac ultrasound) and potential effective intervention (eg Prostacyclin) should be considered in future cases. In this large cohort primary neurodegeneration associated with AR-OP 24 was encountered in only one case. This case illustrated the importance of opthalmo-neurological assessment before HSCT. 25 AR-OP is genetically heterogeneous, although half of the patients have a mutation in the ATP6i gene encoding an essential protein of the vacuolar proton pump in the osteoclasts 2, 3 and some patients have mutations in the CIC-7 chloride channel gene. 5 Prenatal diagnosis in affected families is possible. 26 All children who engrafted after HSCT showed donor-derived osteoclast function. This implies that the defect in AR-OP cases with a normal ATP6i gene is located in the haematopoietic stem cells. No cases have been reported suggesting a stromal defect underlying human AR-OP, [27] [28] [29] as has been described in several animal models, 30, 31 for example, op/op mice with CSF-1 gene mutations. 32 After successful HSCT, careful follow-up is needed. Attention to growth, development, vision and dental care 33, 34 is needed. The issues related to diagnosis and management of children with AR-OP are complex. Further international collaboration as exemplified in our EMBT working party and centralized multidisciplinary management may further improve the outcome of this severe, rare disease.
